Editorials
Does a Positive HLA-B27 Test Increase Your Risk of Mortality? N. Haroon ........................................ 559
Analysis of Bone Samples from Patients with Spondyloarthritides — Identifying Causes of New Bone Formation in Axial Spondyloarthritis
H. Appel, J. Sieper ........................................ 561

Articles
Anti-carbamylated Protein Antibodies Are Present Prior to RA and Are Associated with its Future Diagnosis
Response to Tocilizumab in RA Is Not Influenced by the BMI of the Patient
A Qualitative Investigation of the Barriers to Help-seeking Among Members of the Public Presented with Symptoms of New-onset RA
G. Simons, C.D. Mallen, K. Kumar, R.J. Stack, K. Raza ......................... 585
Urinary Albumin Excretion Is Increased in Patients with RA and Associated with Arterial Stiffness
K. Becetti, A. Oesser, M. Ormseth, et al ............ 593
Prediction of Clinical Response After 1 Year of Infliximab Therapy in RA Based on Disease Activity at 3 Months: Posthoc Analysis of the RISING Study
Intact Calibers of Retinal Vessels in Patients with SSc
Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study
H. Yamazaki, R. Sakai, R. Koike, et al, for the PREVENT Study Group ........... 614
Objective Evaluation of Physical Functioning after TNF Inhibitory Therapy in Patients with Ankylosing Spondyloarthritis: A Selection of 3 Feasible Performance-based Tests

Bone Lineage Proteins in the Entheses of the Midfoot in Patients with Spondyloarthritis
C. Pacheco-Tena, R. Pérez-Tamayo, C. Pineda, et al .... 630
Mortality in American Veterans with the HLA-B27 Gene
Disease Activity in Ankylosing Spondylitis and Associations to Markers of Vascular Pathology and Traditional Cardiovascular Disease Risk Factors: A Cross-sectional Study
I.J. Berg, D. van der Heijde, H. Dagnfinrud, et al ........ 645
2014 Update of CRA/SPARCC Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations
Choosing Wisely: The Canadian Rheumatology Association’s List of 5 Items Physicians and Patients Should Question S.L. Chow, J.C. Thorne, M.J. Bell, et al, on behalf of the CRA Choosing Wisely Committee ........ 682
Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome
A. Knight, K. Hjorton, C. Sundström, et al ............ 690
Variants of the IFI16 Gene Affecting the Levels of Expression of mRNA Are Associated with Susceptibility to Behcet Disease L. Ortiz-Fernández, J.R. García-Lozano, M.A. Montes-Cano, et al ............... 695
The Cost of Research: A Survey of Participating Sites in a Nationwide Registry J.L. Tress, D.D. Sherry ................ 702

Pediatric Rheumatology
Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with JIA
C. Tappeiner, E. Miserochi, B. Bodaghi, et al ............ 706
Macrophage Activation Syndrome in Patients with Systemic JIA under Treatment with Tocilizumab S. Yokota, Y. Itoh, T. Morio, N. Sumitomo, K. Daimaru, S. Minota ........ 712

Contents continued on page xxii